1800 244 735

Helpline (02) 9874 9777

Huntington's disease therapeutics conference 2018 – day 2

Updates from day 2 of the Huntington’s Disease Therapeutics Conference focusing on DNA repair in HD.

Wednesday morning – DNA repair in HD

Good morning from the 2018 HD Therapeutics Conference! Today’s update is relatively brief because the afternoon was focused on poster presentations. The morning session focused on the role of DNA repair in HD – a hot topic these days, thanks to very interesting genetic studies of HD patients. These huge studies demonstrated that genetic variations, outside the HD gene, contribute to how soon HD symptoms occur in people carrying them. Surprisingly, many of these variations were in genes that help cells repair DNA.

Up first, Jong-Min Lee, Massachusetts General Hospital, updates the crowd on the latest results from the GeM-HD consortium – the international group of researchers searching genetic variations that influence HD onset. The GeM-HD consortium uses microchips that read tiny genetic variations across the entire genome of thousands of HD patients. This huge dataset lets them ask the question – are any of these variations influencing how early or late HD occurs? The latest version of the GeM-HD analysis includes 9,000 HD patients! This increase in sample size has enabled them to identify even more variations that modulate HD onset. These variations are strikingly close to even more DNA repair genes. Lee describes a very subtle variation in the sequence of the HD gene itself that also influences the age of HD symptom onset. The most dramatic effect GeM-HD has observed concern a gene called FAN1. Some variations in this gene have a beneficial effect on HD onset, and other variations have a bad effect. This suggests something FAN1 is doing is central to HD progression. Lee provides another stream of evidence which suggests that people who have more Fan1 in their brains have a later onset of HD. This shows the power of doing genetic studies – if we can find a way to bolster the activity of Fan1, it seems likely that it would be beneficial for HD progression.

Guo-Min Li, University of Texas Southwestern, studies a process called “mismatch repair”, one of the ways by which cells repair certain kinds of DNA damage. Mismatch repair allows cells to fix small errors that crop up when cells copy their DNA. Mutations in these genes lead to high rates of cancer, because genetic errors are left un-corrected. Li reminds the audience that while mismatch repair is normally very helpful for cells to remain healthy, it sometimes makes mistakes. One of these is the tendency for long repetitive stretches of DNA to lengthen. The mutation that causes every case of HD – a stretch of the DNA letters “C-A-G” – is one of these repetitive bits of DNA. Li’s lab is studying the process by which mismatch repair of long stretches of CAG makes them longer. Li’s lab has identified a few specific mismatch repair processes that drive CAG expansions – he suggests they may be a good target for new HD treatments.

Lorena Beese, Duke, also studies mismatch repair. Her lab focuses on the precise ways in which the mismatch repair proteins carry out their work – recognizing mistakes, cutting them out and then stitching the DNA back together. The machines that Beese’s lab has described in detail may be future targets for drugs designed to change how they interact with long CAG tracts, like the one in the HD gene.

Peter McKinnon, St. Jude Children’s Research Hospital, is an expert on DNA repair in the brain. He’s addressing the conference on the specific types of DNA damage that occur in the brain. The brain is interesting, from the point of view of DNA repair, because for most of our lives the neurons in our brain don’t divide. This means they can’t use some of the arms of the DNA repair pathways, which only work in dividing cells. McKinnon’s lab studies a specific kind of DNA damage called “base excision repair”, a process for fixing damage to only one of the two strands of DNA.

Partha Sarkar from University of Texas studies the Huntingtin protein and its direct interactions with DNA and DNA-handling proteins. Turns out mutant huntingtin hangs around with a protein called PNKP whose job is to look after DNA. In doing so, it prevents it doing its job. This raises the possibility that the HD mutation accelerates DNA damage.

Latest Research Articles

Huntington’s disease therapeutics conference 2023 – Day 3

Published date: 22 May, 2023

Welcome to the third and final day of HD science, live from Dubrovnik, Croatia! Our Twitter updates are compiled below. Continue to follow live updates for the final day of the conference with the hashtag #HDTC2023.nCheck out our coverage of Day 1 here: https://en.hdbuzz.net/343 and day 2 here: https://en.hdbuzz.net/344. Biomarkers This morning’s session will focus ... Read more

Start here!

Published date: 22 May, 2023

Welcome to HDBuzz! This special page is for people who are new to Huntington’s disease, or new to the world of HD research. Reading the articles linked here will help you pick up the basics of what Huntington’s disease is, and get up to speed with some of the most promising things scientists are doing ... Read more

Huntington’s disease therapeutics conference 2023 – Day 2

Published date: 4 May, 2023

Welcome to the second full day of HD science, live from Dubrovnik! After yesterday’s amazing basic science talks, today begins with a session focused on companies developing new experimental treatments for HD. Our Twitter updates are compiled below. Continue to follow live updates for the rest of the conference with the hashtag #HDTC2023. Check out ... Read more

Huntington’s disease therapeutics conference 2023 – Day 1

Published date: 26 April, 2023

Hello from Dubrovnik, Croatia, where the 2023 CHDI Therapeutics Conference will be taking place from Monday, April 24th, through Thursday, April 27th! This conference is a big one for HD researchers worldwide, from industry, academia, and nonprofit. Dozens of scientists will give talks on all things HD, from genetics, to therapeutics, to clinical trial news. ... Read more

PROOF-HD study of pridopidine ends with negative result

Published date: 25 April, 2023

Top line results of the PROOF-HD study, run by Prilenia Therapeutics and testing pridopidine, have been announced at the American Academy of Neurology convention. Sadly the trial outcome was negative. We recap the history of pridopidine in Huntington’s disease, review the trial results, and figure out where this disappointing result leaves us. The drug: pridopidine ... Read more

Astrocytes: The new star in HD research?

Published date: 19 April, 2023

The most obvious changes related to Huntington’s disease (HD) happen to neurons, the nervous system’s messenger cells that send and receive information throughout the brain and spinal cord. However, many different cell types are affected by HD. A recently published article reviewed research findings from various labs, describing how a specific type of brain cell, ... Read more